No Data
No Data
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Galectin Therapeutics(GALT.US) Director Buys US$5,949.75 in Common Stock
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Express News | Galectin Therapeutics Inc: Navigate Trial Remains on Track for Interim Top-Line Readout Late in Q4 of 2024
Express News | As Of March 31, 2024, Galectin Therapeutics Had $23.6M Of Cash And Cash Equivalents. Additionally, The Company Has $10M Remaining Available Under A $60M Line Of Credit Expected To Provide Cash Runway Into May 2025
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update